On October 14, BIOCYTOGEN-B fell 5.1% in regular trading, trading at HK$53.0, with turnover of HK$64.6865 million.
The latest market catalyst points to continued digestion of sharp weakness in the company’s A-share line and concentrated institutional selling. Public trading data showed the A-share stock previously appeared on the trading list after a steep drop, with the top five sell-side seats all being institutional accounts, totaling about RMB210 million in sales and implying roughly RMB184 million in net institutional selling.
This followed an earlier report that institutional seats occupied the top four sell positions, with combined sales exceeding RMB180 million, reinforcing pressure on H-share sentiment. Position disclosures also showed diverging institutional behavior: Fugui Fund added 64,000 shares on October 7 at about HK$76.97 per share after a prior reduction, while multiple CMB-related entities had reduced holdings in September, highlighting elevated near-term volatility.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments